Dapaglifloz Propaned/Metformin
Brand name: Xigduo Xr
Rank #240 of 500 drugs by total cost
$54.4M
Total Cost
58,629
Total Claims
$54.4M
Total Cost
1,987
Prescribers
$927
Cost per Claim
6,392
Beneficiaries
97,277
30-Day Fills
$27K
Avg Cost/Provider
30
Avg Claims/Provider
About Dapaglifloz Propaned/Metformin
Dapaglifloz Propaned/Metformin (sold as Xigduo Xr) was prescribed 58,629 times by 1,987 Medicare Part D providers in 2023, costing the program $54.4M. At $927 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 237 | Benralizumab (Fasenra Pen) | $54.8M | 9,334 |
| 238 | Netarsudil Mesylat/Latanoprost (Rocklatan) | $54.7M | 103,171 |
| 239 | Amifampridine Phosphate (Firdapse) | $54.4M | 1,203 |
| 240 | Dapaglifloz Propaned/Metformin (Xigduo Xr) | $54.4M | 58,629 |
| 241 | Buspirone Hcl (Buspirone Hcl) | $53.7M | 2,868,147 |
| 242 | Oxybutynin Chloride (Oxybutynin Chloride Er) | $53.4M | 1,872,901 |
| 243 | Raltegravir Potassium (Isentress) | $53.0M | 25,491 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology